Why the study?
Is left atrial appendage occlusion with the Watchman FLX device noninferior to direct oral anticoagulants for preventing the composite of stroke, systemic embolism, and cardiovascular death in patients with nonvalvular atrial fibrillation?
Is left atrial appendage occlusion with the Watchman FLX device noninferior to direct oral anticoagulants for preventing the composite of stroke, systemic embolism, and cardiovascular death in patients with nonvalvular atrial fibrillation?
Answers are grounded in this paper and cite their sources.
This paper reappraises the noninferiority margin and conclusions of the CHAMPION-AF trial comparing left atrial appendage occlusion to direct oral anticoagulants in nonvalvular atrial fibrillation.
The recently published CHAMPION-AF trial compared left atrial appendage occlusion (LAAO) with the Watchman FLX device (Boston Scientific, Inc) with direct oral anticoagulants (DOACs) for a composite of stroke, systemic embolism, and cardiovascular death in patients with nonvalvular atrial fibrillation and concluded that LAAO was noninferior.1 The event rate was 5.7% in the LAAO arm and 4.8% in the DOAC arm, and the upper bound of the 95% confidence interval (CI) for the absolute risk difference (2.6%) fell below the prespecified 4.8% margin.
No takes yet. Share an insight, caveat, or question.
Shah et al. (2026) conducted an editorial in Nonvalvular atrial fibrillation. Left atrial appendage occlusion (Watchman FLX) vs. Direct oral anticoagulants (DOACs) was evaluated on Composite of stroke, systemic embolism, and cardiovascular death (95% CI upper bound 2.6% for absolute risk difference).
Synapse has enriched 10 related papers. Consider them for comparative context: